Drug intelligence / Profile preview

Zixin Biqiu Granules

Development stage: Phase 3
Lead developer: Lianyungang Kanion
Administration: Oral

Overview

Zixin Biqiu Granules is a Traditional Chinese Medicine (TCM) developed by Jiangsu Kanion Pharmaceutical Co., Ltd. for the treatment of persistent allergic rhinitis. The formulation is designed as granules for oral administration and aims to alleviate clinical symptoms such as nasal congestion, sneezing, and rhinorrhea. The drug has been evaluated in Phase II clinical trials (e.g., CTR20190600) in China to assess its safety profile and clinical efficacy, as well as to determine the optimal dosage for subsequent Phase III development.

Brand names: Zixin Biqiu Granules
Other names: 紫辛鼻鼽颗粒

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CASP3 (Caspase-3)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)JUN (Transcription factor Jun)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on Zixin Biqiu Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zixin Biqiu Granules.